Radiochemical Diagnosis of Adrenal Disease

References

• Shapiro B., Gross M. D., Sandler M. P., Falke T. H. M., Shaff M. I. The adrenal scan revisited: a current status report on radiotracers and clinical utility, correlative imaging. Nuclear Medicine Annual 1987, L. M. Freeman, H. S. Weissmann. Raven Press, New York, NY 1987; 193
   Google Scholar
• Gross M. D., Shapiro B., Thrall J. H., Freitas J. E., Beierwaltes W. H. The scintigraphic imaging of endocrine organs. Endocr. Rev. 1984; 5: 221
   PubMedGoogle Scholar
• Thrall J. H., Freitas J. E., Beierwaltes W. H. Adrenal scintigraphy. Sem. Nucl. Med. 1978; 8: 23
   PubMedGoogle Scholar
• McEwan A. J., Shapiro B., Sisson J. C., Beierwaltes W. H., Ackery D. M. Radioiodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Sem. Nucl. Med. 1985; 15: 132
   PubMedGoogle Scholar
• Sarkar S. D., Cohen E. L., Beierwaltes W. H., Ju R. D., Casper R., Gold E. N. A new and superior adrenal imaging agent 131-I-6B-iodomethyl-19-norcholesterol (NP-59) evaluation in humans. J. Clin. Endocrinol. Metab. 1977; 45: 353
   PubMedGoogle Scholar
• Basmadjian G. P., Hetzel K. R., Ice R. D., Beierwaltes W. H. Synthesis of a new adrenal cortex imaging agents 6B I-131-iodomethyl-19-norcholest-5(10)-EN-3B-ol (NP-59). J. Label Comp. Radiopharm. 1975; 11: 427
   Google Scholar
• Hawkins L. A., Britton K. E., Shapiro B. Selenium-75 selenomethyl cholesterol: a new agent for quantitative functional scintigraphy of the adrenals. Br. J. Med. 1980; 53: 883
   Google Scholar
• Shapiro B., Britton K. E., Hawkins L. A., Edwards C. E. Clinical experience with Se-selenomethylnorcholesterol adrenal imaging. Clin. Endocrinol. 1981; 15: 19
   PubMedGoogle Scholar
• Lieberman L. M., Beierwaltes W. H., Conn J. W., Ansari A., Nishiyama H. Diagnosis of adrenal disease by visualization of human adrenal glands with I-131-19-iodocholesterol. N. Engl. J. Med. 1971; 285: 1387
   PubMed Web of Science ®Google Scholar
• Gross M. D., Valk T. W., Swanson D. P., Thrall J. H., Grekin R. J., Beierwaltes W. H. The role of pharmacologic manipulation in adrenal cortical scintigraphy. Semin. Nucl. Med. 1981; 9: 128
   Google Scholar
• Gross M. D., Freitas J. E., Swanson D. P., Brady T., Beierwaltes W. H. The normal dexamethasone suppression adrenal scintiscan. J. Nucl. Med. 1979; 20: 1131
   PubMedGoogle Scholar
• Gordon L., Mayfield R. K., Levine J. G., Lopes-Virella M. F., Sagel J., Buse M. G. Failure to visualize adrenal glands in a patient with bilateral adrenal hyperplasia. J. Nucl. Med. 1980; 21: 49
   PubMed Web of Science ®Google Scholar
• Valk T. W., Gross M. D., Swanson D. P., Freitas J. E., Schteingart D. E., Beierwaltes W. H. The relationship of serum lipids to adrenal gland uptake of 6B-131-I-iodomethyl-19-norcholesterol in Cushing's syndrome. J. Nucl. Med. 1980; 21: 1069
   PubMedGoogle Scholar
• Lynn M. D., Gross M. D., Shapiro B., Bassett D. The influence of hypercholesterolemia on the adrenal uptake and metabolic handling of I-131-6B-iodomethyl-19-norcholesterol (NP-59). Nucl. Med. Res. Comm. 1986; 7: 631
   PubMedGoogle Scholar
• Lynn M. D., Gross M. D., Shapiro B. Enterohepatic circulation and distribution of 131-I-6B-iodomethyl-19-norcholesterol (NP-59). Nucl. Med. Res. Comm. 1986; 7: 625
   PubMedGoogle Scholar
• Shapiro B., Nakajo M., Gross M. D., Freitas J. E., Copp J. E., Beierwaltes W. H. Value of bowel preparation in adrenocortical scintigraphy with NP-59. J. Nucl. Med. 1983; 24: 732
   PubMedGoogle Scholar
• Wieland D. M., Wu J., Brown L. E., Mangner T. J., Swanson D. P., Beierwaltes W. H. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [123I]iodobenzylguanidine. J. Nucl. Med. 1980; 21: 349
   PubMed Web of Science ®Google Scholar
• Wieland D. M., Brown L. E., Tobes M. C., Rogers W. L., Marsh D. D., Mangner T. J., Swanson D. P., Beierwaltes W. H. Imaging the primate adrenal medullae with [123I] and [131I] meta-iodobenzylguanidine: concise communication. J. Nucl. Med. 1981; 22: 358
   PubMed Web of Science ®Google Scholar
• Shapiro B., Wieland D. M., Brown L. E., Nakajo M., Sisson J. C., Beierwaltes W. H. 131-I-meta-iodobenzylguanidine (MIBG) adrenal medullary scintigraphy: interventional studies. Intervential Nuclear Medicine, R. P. Spencer. Grune and Stratton, New York 1984; 451
   Google Scholar
• Jacques S., Jr., Tobes M. C., Sisson J. C., Baker J. A., Wieland D. M. Comparison of the sodium dependence of uptake of meta-iodo-benzlyguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol. Pharmacol. 1984; 26: 539
   PubMedGoogle Scholar
• Gasnier B., Rosin M. P., Scherman D., Coornaert S., Desplanches G., Henry J. P. Uptake of meta-iodobenzlyguanidine by bovine chromaffin granule membranes. Mol. Pharmacol. 1986; 29: 275
   PubMed Web of Science ®Google Scholar
• Nakajo M., Shimabakuro K., Yoshimura H., Yonekura R., Nakabeppa Y., Tanoue P., Shi-nohara S. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J. Nucl. Med. 1986; 27: 84
   PubMed Web of Science ®Google Scholar
• Guilloteau D., Baulieu J-L., Huguet F., Viel C., Chambon C., Valat C., Baulieu F., Itti R., Pourcelot L., Narcisse G., Besnard J-C. Metaiodobenzylguanidine adrenal medulla localization: Autoradiographic and pharmaceutical studies. Eur. J. Nucl. Med. 1984; 9: 278
   PubMedGoogle Scholar
• Tobes M. C., Jacques S., Wieland D. M., Sisson J. C. Effect of uptake-one-inhibitors on the uptake of norepinephrine and meta-iodo-benzylguanidine. J. Nucl. Med. 1985; 26: 897
   PubMed Web of Science ®Google Scholar
• Sherman P. S., Fisher S. J., Wieland D. M., Sisson J. C. Over the counter drugs block heart accumulation of MIBG. J. Nucl. Med. 1985; 26: P35
   Google Scholar
• Munkner T. 131I-Meta-Iodobenzylguanidine scintigraphy of neuroblastoma. Semin. Nucl. Med. 1985; 15: 154
   PubMedGoogle Scholar
• Feldman J. M., Frankel N., Coleman R. E. Platelet uptake of the pheochromocytoma-scanning agent 131-I-meta-iodobenzylguanidine. Metabolism 1984; 33: 397
   PubMedGoogle Scholar
• Mangner T. J., Tobes M. C., Wieland D. M., Sisson J. C., Shapiro B., Beierwaltes W. H. Metabolism of meta-I-131-iodobenzylguanidine in patients with metastatic pheochromocytoma: Concise Communication. J. Nucl. Med. 1986; 27: 37
   PubMedGoogle Scholar
• Tobes M. C., Shapiro B., Meyers L., Mallette S. Pharmacokinetics of I-131-meta-iodobenzylguanidine (MIBG) in an anephric patient. presented at European Nuclear Medicine Congress, LondonEngland, September, 3 to 61985
   Google Scholar
• Shapiro B., Sisson J. C., Kalff V., Glowniak J. V., Satterlee W., Glazer G., Francis I., Bowers R., Thompson N. W., Orringer M., Gross M. D., Beierwaltes W. H. The location of middle mediastinal pheochromocytomas. J. Thoracic Cardiovasc. Surgery 1984; 87: 816
   Google Scholar
• Nakajo M., Shapiro B., Sisson J. C., Swanson D. P., Beierwaltes W. H. Salivary gland accumulation of meta-131-iodobenzylguanidine. J. Nucl. Med. 1984; 25: 2
   PubMedGoogle Scholar
• Sipila L. N., Carey J. E., Shapiro B., Jacobson A. P. Health physics aspects of I-131-meta-iodobenzylguanidine therapies-a prototype for I-131-radio-labeled antibody therapies. Med. Physics 1985; 12: 520
   Google Scholar
• Carey J. E., Thrall J. H., Freitas J. E., Beierwaltes W. H. Absorbed dose to the human adrenal for iodomethyl-norcholesterol (1-131) “NP-59”. J. Nucl. Med. 1979; 20: 60
   PubMedGoogle Scholar
• Swanson D. P., Carey J. E., Brown L. E., Kline R. C., Wieland D. M., Thrall J. H., Beierwaltes W. H. Human absorbed dose calculations for iodine 131 and iodine 123-labeled metaiodobenzylguanidine (mlBG): a potential myocardial and adrenal medulla imaging agent. Proceedings of the Third International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN. HHS Publication FDA 81-8166, Bethesda, MD 1981; 213
   Google Scholar
• Myers W. G. Radioiodine-123 for medical research and diagnosis. Recent Advances in Nuclear Medicine-Progress in Atomic Medicine, J. H. Lawrence. Grune and Stratton, Inc., New York, NY 1976; 133
   Google Scholar
• Lynn M. D., Shapiro B., Sisson J. C., Swanson D. P., Mangner T. J., Wieland D. M., Meyers L. J., Beierwaltes W. H. Portrayal of pheochromocytoma and normal human adrenal medulla by m-[I-123]iodomethylguanidine: Concise Communication. J. Nucl. Med. 1984; 25: 436
   PubMed Web of Science ®Google Scholar
• Nelson D. H. The Adrenal Cortex: Physiological Function and Disease. W. B. Saunders, Philadelphia 1980; 48
   Google Scholar
• Nelson D. H. The Adrenal Cortex: Physiological Function and Disease. W. B. Saunders, Philadelphia, 134
   Google Scholar
• Skeggs L. T., Dorer P. E., Kahn J. R. The biochemistry of the renin angiotensin system and its role in hypertension. Am. J. Med. 1976; 60: 737
   PubMed Web of Science ®Google Scholar
• Grekin R. J., Gross M. D. Endocrine hypertension. Comp. Ther. 1983; 9: 65
   PubMedGoogle Scholar
• Streeten D. D., Tomycz N., Anderson G. N. Reliability of screening methods for the diagnosis of primary aldosteronism. Am. J. Med. 1979; 67: 403
   PubMed Web of Science ®Google Scholar
• Feriss J. B., Bevers D. G., Brown J. J., Davies D. L., Fraser R., Mason P., Nefille A. M., Robertson J. I.S. Clinical, biochemical and pathological features of low-renin (primary) hyperaldosteronism. Am. Heart J. 1978; 95: 375
   PubMedGoogle Scholar
• Weinberger M. H., Grim C. E., Hollifield J. W., Kern D. C., Ganguly A., Kramer N. J., Yune H. Y., Wellman H., Donohue J. P. Primary aldosteronism: diagnosis, localization and treatment. Ann. Intern. Med. 1979; 90: 386
   PubMed Web of Science ®Google Scholar
• Ganguly A., Grim C. E., Weinberger M. H. Primary aldosteronism: the etiologic spectrum of disorders and their clinical differentiation. Arch. Intern. Med. 1982; 142: 813
   PubMedGoogle Scholar
• Shenker Y., Gross M. D., Grekin R. J., Rosen S. G., Sanfield J. A., Shapiro B., Samuels B., Strodel W., Thompson N. W., Beals T. F., Lloyd R. V. The scintigraphic localization of mineralocorticoid-producing adrenal cortical carcinoma. J. Endocrinol. Invest. 1986; 9: 115
   PubMedGoogle Scholar
• Gross M. D., Shapiro B., Grekin R. J., Freitas J. E., Glazer G., Beierwaltes W. H., Thompson N. W. Scintigraphic localization of adrenal lesions in primary aldosteronism. Am. J. Med. 1984; 77: 839
   PubMed Web of Science ®Google Scholar
• Coon J. W., Morita R., Cohen E. L., Beierwaltes W. H., McDonald W. J., Herwing K. R. Primary aldosteronism: photoscanning of tumors after administration of 1311-iodocholesterol. Arch. Int. Med. 1972; 129: 417
   PubMedGoogle Scholar
• Koral K. F., Sarkar S. D. An operator-independent method for background subtraction in adrenal uptake measurements. J. Nucl. Med. 1977; 18: 925
   PubMedGoogle Scholar
• Gross M. D., Shapiro B., Freitas J. E. The limited significance of asymmetrical adrenal visualization on dexamethasone suppression scintigraphy. J. Nucl. Med. 1985; 26: 43
   PubMed Web of Science ®Google Scholar
• Gross M. D., Grekin R. J., Brown L. E., Marsh D. D., Beierwaltes W. H. The relationship of adrenal iodocholesterol uptake to adrenal zona glomerulosa function. J. Clin. Endocrinol. Metab. 1981; 52: 612
   PubMedGoogle Scholar
• Geisinger M. A., Zelch M. G., Bravo E. L., Risius B. F., Odonovan P. B., Borkowski G. P. Primary hyperaldosteronism: comparison of CT, adrenal venography and venous sampling. AJR 1983; 141: 299
   PubMed Web of Science ®Google Scholar
• Sample U. F., Sarti D. A. Computed tomography and gray scale ultrasonography of the adrenal gland: a comparative study. Radiology 1978; 128: 377
   PubMedGoogle Scholar
• Dunnick N. R., Doppman J. L., Gill J. R., Strott C. A., Keiser H. R., Brennan M. F. Localization of functional adrenal tumors by computed tomography and venous sampling. Radiology 1982; 142: 429
   PubMed Web of Science ®Google Scholar
• Dunnick N. R., Schaner E. G., Doppman J. L., Strott C. A., Gill J. R., Javadpour N. Computed tomography in adrenal tumors. AJR 1979; 132: 43
   PubMed Web of Science ®Google Scholar
• Huebner K. H., Treugut H. Adrenal cortex dysfunction. CT findings. Radiology 1984; 150: 195
   PubMedGoogle Scholar
• Guerin C. K., Wahner H. W., Gorman C. A., Carpenter P. C., Sheedy P. F. Computed tomographic scanning versus radioisotope imaging in adrenocortical diagnosis. Am. J. Med. 1983; 75: 653
   PubMedGoogle Scholar
• White E. A., Schambelan M., Rost C. R., Biglieri E. G., Moss A. A., Korobkin M. Use of computed tomography in diagnosing the cause of primary aldosteronism. N. Engl. J. Med. 1980; 303: 1503
   PubMed Web of Science ®Google Scholar
• Davis P. L., Hricak H., Bradley W. H., Jr. Magnetic resonance imaging of the adrenal glands. Radiol. Clin. North Am. 1984; 22: 892
   Google Scholar
• Schultz U., Haaga J. R., Fletcher B. D., Alfidi K. J., Schultz M. A. Magnetic resonance imaging of the adrenal glands: A comparison with CT. AJR 1984; 143: 1235
   PubMedGoogle Scholar
• Falke T. H. M., te Strake L., Shaff M. I., Sandler M. P., Kulkarni M. V., Partain C. L., Nieuwenhuizen-Kruseman A. C., James S. E., Jr. MR imaging of the adrenals: correlation with computed tomography. J. Comput, Tomogr. 1986; 10: 242
   Google Scholar
• Dige-Petersen H., Munkner T., Fogh J., Blichert-Toft M., Lund J. O. 1311-19-iodocholesterol scintigraphy of the adrenal cortex. Acta Endocrinol 1975; 80: 81
   PubMedGoogle Scholar
• Conn J. W., Cohen E. L., Herwig K. R. TA dexamethasone-modified adrenal scintiscans in hyporeninemic aldosteronism (tumor vs. hyperplasia). A comparison with adrenal venography and adrenal venous aldosterone. J. Lab. Clin. Med. 1976; 88: 841
   PubMedGoogle Scholar
• Troncone L. Radioiodocholesterol scintigraphy in adrenal gland tumors. Eur. J. Nucl. Med. 1980; 5: 345
   PubMedGoogle Scholar
• Ryo U., Johnston A. S., Kim I., Pinsky S. M. Adrenal scanning and uptake with 1311-6B-iodomethyl-norcholesterol. Radiology 1978; 128: 157
   PubMedGoogle Scholar
• Freitas J. E., Grekin R. J., Thrall J. H., Gross M. D., Swanson D. P., Beierwaltes W. H. Adrenal imaging with iodomethyl-norchlesterol (1-131) in primary aldosteronism. J. Nucl. Med. 1979; 20: 7
   PubMedGoogle Scholar
• Miles J. M., Wahner H. W., Carpenter P. C., Salassa R. M., Northcutt R. C. Adrenal scintiscanning with NP-59: a new radioiodinated cholesterol agent. Mayo Clin. Proc. 1979; 54: 321
   PubMedGoogle Scholar
• Herf S. M., Teates D. C., Tegtmeyer C. J., Vaughan E. D., Ayers C. R., Carey R. M. Identification and differentiation of surgically correctable hypertension due to primary aldosteronism. Am. J. Med. 1979; 67: 397
   PubMed Web of Science ®Google Scholar
• Leger F. A., Requeda E., Reach G., Plovin P. F., Savoie J.-C. Scintigraphic corticosurrenalinenne au 131I-19-iodocholesterol. Nouv. Presse Med. 1981; 10: 395
   PubMedGoogle Scholar
• Hoefnagels W. H., Claessens R. A., Corstens F. H., Drayer J. I., Kazem I., Kloppenborg P. W. Adrenal scintigraphy in primary aldosteronism. Improved visualization after long-term pre-treatment with dexamethasone. Nuklearmedizin 1981; 20: 76
   PubMedGoogle Scholar
• Chrousos G. Differential diagnosis of Cushing's syndrome. Ann. Int. Med. 1985; 102: 346
   Google Scholar
• Scott H. W., Jr., Abumrad N. N., Orth D. N. Tumors of the adrenal cortex and Cushing's syndrome. Ann. Surg. 1984; 201: 586
   Google Scholar
• Skalkeas G., Gogas J. G., Sechas M. N., Kostakis M., Pavlatos F. Cushing's syndrome: analysis of 18 cases. Am. J. Surg. 1982; 143: 363
   PubMedGoogle Scholar
• Aron D. C., Findling J. W., Fitzgerald P. A., Forsham P. H., Wilson C. B., Tyrrell J. B. Cushing's syndrome: problems in management. Endocr. Rev. 1982; 3: 229
   PubMedGoogle Scholar
• Beierwaltes W. H., Liebermann L. M., Ansari A. N., Nishyama R. Visualization of the human adrenal glands in vivo by scintillation scanning. JAMA 1971; 216: 275
   PubMed Web of Science ®Google Scholar
• Baba H. CT of the normal adrenal glands and image diagnosis of the adrenal diseases. Nippon Acta Radiologica 1982; 42: 938
   PubMedGoogle Scholar
• Freitas J. E., Thrall J. H., Swanson D. P., Rifai A., Beierwaltes W. H. Normal adrenal asymmetry: explanation and interpretation. J. Nucl. Med. 1978; 19: 149
   PubMedGoogle Scholar
• Gross M. D., Valk T., Freitas J. E., Swanson D. P., Schteingart D. E., Beierwaltes W. H. The relationship of adrenal iodomethylnorcholesterol uptake to indices of adrenal cortical function in Cushing's Syndrome. J. Clin. Endocrinol. Metab. 1981; 52: 1062
   PubMedGoogle Scholar
• Freitas J. E., Herwig K. R., Cerny I. C., Beierwaltes W. H. Preoperative localization of adrenal remnants. Surg. Gynecol. Obstet. 1977; 145: 705
   PubMedGoogle Scholar
• Seabold J. E., Haynie T. P., Deasis D. N., Samaan N. A., Glenn H. J., Jahns M. F. Detection of metastatic adrenal carcinoma using 1-131-6B-iodomethyl-19-norcholesterol total body scans. J. Clin. Endocrinol. Metab. 1977; 45: 788
   PubMedGoogle Scholar
• Erhmann D., Gross M. D., Shapiro B., Freitas J., Schteingart D. The location of abnormal adrenal function in ACTH-independent Cushing's syndrome. J. Nucl. Med. 1986; 25: A131
   Google Scholar
• Fig L. M., Gross M. D., Shapiro B., Ehrmann D., Freitas J. E., Schteingart D. E., Glazer G. Scintigraphic localization of the abnormal adrenals in ACTH independent Cushing's syndrome. J. Nucl. Med. 1987; 28: 640
   Google Scholar
• Larsen J. L., Cathey W. J., Odell W. D. Primary adrenocortical nodular dysplasia, a distinct subtype of Cushing's syndrome: case report and review of the literature. Am. J. Med. 1986; 80: 976
   PubMed Web of Science ®Google Scholar
• Smals A. G. H., Pieters G. F. F. M., Van Haelst V. J. G., Kloppenborg P. W. C. Macronodular adrenocortical hyperplasia in long-standing Cushing's disease. J. Clin. Endocrinol. Metab. 1984; 58: 25
   PubMedGoogle Scholar
• Schteingart D. E., Tsao H. S. Coexistence of pituitary adrenocorticotrophin-dependent Cushing's syndrome with a solitary adenoma. J. Clin. Endocrinol. Metab. 1980; 50: 961
   PubMed Web of Science ®Google Scholar
• Shapiro B., Grant D. B., Britton K. E. 75Se-selenomethylcholesterol uptake in familial congential Cushing's syndrome. J. Nucl. Med. 1982; 23: 799
   PubMedGoogle Scholar
• Kaplowitz P. B., Carpenter R., Newsome H. H., Downs R. W. Cushing's syndrome resulting from primary pigmented nodular adrenocortical disease. Am. J. Dis. Childhood 1986; 140: 1072
   PubMedGoogle Scholar
• Teding Van Berkhout F., Croughs R. J., Kater L., Schuurman H. J., Gmelig-Meyling F. J., Kooyman C. D., van der Gaag R. D., Jolink D., Drexhage H. A. Familial Cushing's syndrome due to nodular hyperplasia. A putative receptor-antibody disease?. Clin. Endocrinol. (Oxf.) 1986; 24: 299
   PubMedGoogle Scholar
• Doppman J. L., Miller D. L., Dwyer A. J., Loughlin T., Nieman L., Cutler G. B., Chrousos G. P., Oldfield E., Loriaux D. L. Macronodular adrenal hyperplasia in Cushing disease. Radiology 1988; 166: 347
   PubMedGoogle Scholar
• Joffe S. N., Brown C. Nodular adrenal hyperplasia and Cushing's syndrome. Surgery 1983; 94: 919
   PubMedGoogle Scholar
• Watson N. E., Cowan R. J., Chitton H. M. The utility of adrenal scintigraphy in Cushing's syndrome and hyperaldosteronism. Clin. Nucl. Med. 1985; 10: 539
   PubMedGoogle Scholar
• Sudell C. J., Blake G. M., Gossage A. A. R., Cullen D. R., Munro D. S. Adrenal scintigraphy with 75Se-selenonorcholesterol: a review. Nucl. Med. Commun. 1985; 6: 519
   PubMedGoogle Scholar
• Sarkar S., Simmons B., Kazam E. Iodocholesterol scintigraphy and computed tomography (CT) in Cushing's syndrome and primary aldosteronism. J. Nucl. Med. 1987; 28: 640
   Google Scholar
• Givens J. R. Hirsutism and hyperandrogenism. Adv. Intern. Med. 1976; 1: 221
   Google Scholar
• Vermuelen A., Rubens R. Adrenal virilism. The Adrenal Gland, Y. H. T. James. Raven Press, New York, NY 1979; 259
   Google Scholar
• Gross M. D., Wortsman J., Shapiro B., Meyers L. C., Woodbury M. C., Ayers J. W. T. Scintigraphic evidence of adrenal cortical dysfunction in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1985; 62: 197
   Google Scholar
• Gross M. D., Freitas J. E., Swanson D. P., Beierwaltes W. H., Woodbury M., Schteingart D. E. Dexamethasone suppression (DS) adrenal scintigraphy in hyperandrogenism. J. Nucl. Med. 1981; 22: 12
   PubMedGoogle Scholar
• Gross M. D., Shapiro B., Freitas J. E., Ayers J., Swanson D. P., Woodbury M. C., Schteingart D. E., Beierwaltes W. H. The relationship of I-131-6B-iodomethyl-19-norcholesterol (NP-59) uptake to indices of androgen secretion in women with hyperandrogenism. Clin. Nucl. Med. 1984; 9: 264
   PubMedGoogle Scholar
• Ripley S. D., Gross M. D., Shapiro B., Barkan A., Freitas J. E., Woodbury M. C., Schteingart D. E., Ayers J. W.T. Scintigraphic localization of androgen-secreting neoplasms. Eur. J. Nucl. Med. 1985; 11: A27
   Google Scholar
• Carpenter P. C., Wahner H. W., Salassa R. M., Duick D. S. Demonstration of steroid producing gonadal tumors by external scanning with the use of NP-59. Mayo. Clin. Proc. 1979; 54: 332
   PubMedGoogle Scholar
• Copeland P. M. The incidentially discovered adrenal mass. Ann. Int. Med. 1983; 98: 940
   PubMed Web of Science ®Google Scholar
• Abecassis M., McLoughlin M., Langer B., Kudlow J. E. Seredipitous adrenal masses: prevalence, significance and management. Am. J. Surg. 1985; 149: 783
   PubMedGoogle Scholar
• Neville A. M. The nodular adrenal. Invest. Clin. Pathol. 1978; 1: 99
   PubMedGoogle Scholar
• Glazer H. S., Weyman P. J., Sagel S. S., Levity R. G., McClennan B. C. Non-functioning adrenal mases: incidental discovery on computed tomography. AJR 1982; 139: 81
   PubMed Web of Science ®Google Scholar
• Mitnick J. S., Bosniak M. A., Megibow A. J., Naidich D. P. Non-functioning adrenal masses adenomas discovered incidentally on computed tomography. Radiology 1983; 148: 495
   PubMedGoogle Scholar
• Hussain S., Belldegnim A., Seltzer S. E., Richie J. P., Abrams H. L. CT diagnosis of adrenal abnormalities in patients with non-primary non-adrenal malignancies. Eur. J. Radiol. 1986; 6: 127
   PubMedGoogle Scholar
• Oliver T. W., Bernardino M. E., Miller J. I., Mansour K., Green D., Davis W. A. Isolated adrenal masses in non-small-cell bronchogenic carcinoma. Radiology 1984; 153: 217
   PubMedGoogle Scholar
• Hedeland H., Ostberg G., Hokfelt B. On the prevalence of adrenocortical adenomas in autopsy material in relation to hypertension and diabetes. Acta Med. Scan. 1968; 194: 211
   Google Scholar
• Abrams H. L., Spiro R., Goldstein N. Metastases in carcinoma: analysis of 1000 autopsied cases. J. Urol. 1959; 81: 711
   PubMedGoogle Scholar
• Hussain S., Belldegrun A., Seltzer S. E., Richie J. P., Gittes R. F., Abrams H. L. Differentiation of malignant from benign adrenal masses: predictive indices on computed tomography. AJR 1985; 144: 61
   PubMedGoogle Scholar
• Baker M. E., Spritzer C., Blinder R., Herfkens R. J., Leight G. S., Dtinnick N. R. Benign adrenal lesions mimicking malignancy on MR imaging; report of two cases. Radiology 1987; 163: 669
   PubMedGoogle Scholar
• Guerrero L. A. Diagnostic and therapeutic approach to incidental adrenal masses. Urology 1985; 26: 435
   PubMedGoogle Scholar
• Prinz R. A., Brooks M. H., Churchill R., Graner J. L., Lawrence A. M., Paloyan E., Sparagana M. Incidental asymptomatic adrenal masses detected by computed tomographic scanning. Is operation required?. JAMA 1982; 248: 701
   PubMed Web of Science ®Google Scholar
• Katz R. L., Shirkhoda A. Diagnostic approach to incidental adrenal nodules in the cancer patient Results of a clinical, radiologic and fine needle aspiration study. Cancer 1985; 55: 1995
   PubMedGoogle Scholar
• Berkman W. A., Bernardino M. E., Sewell C. W., Price R. B., Sones P. J. The computed tomography-guided adrenal biopsy. An alternative to surgery in adrenal mass diagnosis. Cancer 1984; 53: 2098
   PubMedGoogle Scholar
• Heaston D. K., Handel D. B., Ashton P. R., Korobkin M. Narrow gauge needle aspiration of solid adrenal masses. AJR 1982; 138: 1143
   PubMed Web of Science ®Google Scholar
• Bernardino M. E., Walther M. M., Phillips V. M., Graham S. D., Sewell C. W., Gedgaudas-McClees K., Baumgartner B. R., Torres W. E., Erwin B. C. CT-guided adrenal biopsy: accuracy, safety and indication. AJR 1985; 144: 67
   PubMedGoogle Scholar
• Yankaskas B. C., Staab E. V., Craven M. B., Blatt P. M., Sokhandan M., Carney C. N. Delayed complications from fine-needle biopsies of solid masses of the abdomen. Invest. Radiol. 1986; 21: 325
   PubMed Web of Science ®Google Scholar
• Gross M. D., Wilton G. P., Shapiro B., Cho K., Samuels B. I., Bouffard J. A., Glazer G., Grekin R. J., Brady T. Functional and scintigraphic evaluation of the silent adrenal mass. J. Nucl. Med. 1987; 28: 1401
   PubMedGoogle Scholar
• Francis I. R., Smid A., Gross M. D., Naylor B., Glazer G. M. Functional/morphological evaluation of the adrenal mass in the oncologic patient. Radiology 1988; 166: 353
   PubMedGoogle Scholar
• Rizza R. A., Wanner W. H., Spelsberg T. C., Northcutt R. C., Moses H. L. Visualization of nonfunctioning adrenal adenomas with iodocholesterol: possible relationship to subcellar distribution of tracer. J. Nucl. Med. 1978; 19: 458
   PubMedGoogle Scholar
• Ouraishi M. A., Costanzi J. J., Balachandran S. Iodocholesterol adrenal scanning for the detection of adrenal metastases in lung cancer and its clinical significance. Cancer 1981; 48: 714
   PubMedGoogle Scholar
• Berliner L., Bosniak M. A., Megibow W. Adrenal pseudotumors on computed tomography. J. Comput. Tomogr. 1982; 6: 281
   Google Scholar
• Mitty H. A., Cohen B. A., Sprayregen S., Schwartz K. Adrenal pseudo-tumors on CT due to dilated portosystemic veins. AJR 1983; 141: 727
   PubMedGoogle Scholar
• Schwartz A. N., Goiney R. C., Graney D. O. Gastric diverticulum simulating an adrenal mass: CT appearance and embryogenesis. AJR 1986; 146: 553
   PubMedGoogle Scholar
• Charbonnel B., Chatal J. F., Ozanne P. Does the corticoadrenal adenoma with “pre-Cushing's syndrome” exist?. J. Nucl. Med. 1981; 22: 1059
   PubMed Web of Science ®Google Scholar
• Beierwaltes W. H., Sturman M. F., Ryo U., Ice R. D. Imaging functional nodules of the adrenal glands with 131I-19-iodocholesterol. J. Nucl. Med. 1974; 15: 246
   PubMedGoogle Scholar
• Fukushima D. K., Gallagher T. F. Steroid production in “nonfunctioning” adrenal cortical tumors. J. Clin. Encrinol. Metab. 1963; 23: 923
   PubMedGoogle Scholar
• Sisson J. C., Frager M. S., Valk T. W., Gross M. D., Swanson D. P., Wieland D. M., Tobes M. C., Beierwaltes W. H., Thompson N. W. Scintigraphic localization of pheochromocytoma. N. Engl. J. Med. 1981; 305: 12
   PubMed Web of Science ®Google Scholar
• Shapiro B., Sisson J. C., Beierwaltes W. H. Experience with the use of I-131-metaiodobenzylguani-dine for locating pheochromocytomas. Nuclear Medicine and Biology (Proceedings of the Third World Congress of Nuclear Medicine and Biology), C. Raynaud. Pergamon Press, Paris 1982; 2: 1265
   Google Scholar
• Nakajo M., Shapiro B., Copp J. E., Kalff V., Gross M. D., Sisson J. C., Beierwaltes W. H. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131] Iodobenzylguanidine (I-131-MIBG) in man: evaluation by scintigraphy. J. Nucl. Med. 1983; 24: 672
   PubMed Web of Science ®Google Scholar
• Nakajo M., Shapiro B., Glowniak J. V., Sisson J. E., Beierwaltes W. H. Inverse relationship between cardiac accumulation of meta-131-I-iodobenzyl-guanidine (I-131-MIBG) and circulating catecholamines: observations in patients with suspected pheochromocytoma. J. Nucl. Med. 1983; 24: 1127
   PubMedGoogle Scholar
• Brown M. J., Fuller R. W., Lavender J. P. False positive diagnosis of bilateral pheochromocytoma by iodine-131-labelled meta-iodobenzylguanidine. Lancet 1984; 1: 56
   PubMedGoogle Scholar
• Bomanji J., Britton K. E. Uterine uptake of Iodine-123 metaiodobenzylguanidine during the menstrual phase of uterine cycle. Clin. Nucl. Med. 1987; 12: 601
   PubMedGoogle Scholar
• Lindberg S., Ernest I., Fjalling M., Jacobsson L. The value of late images in I-131-metaiodoben-zylguanidine (I-131-MIBG) scanning of the adrenal medulla. Eur. J. Nucl. Med. 1985; 11: A28
   Google Scholar
• Lynn M. D., Shapiro B., Sisson J. C., Beierwaltes W. H., Meyers L. J., Ackermann R., Mangner T. J. Pheochromocytoma and normal adrenal medulla: improved visualization with I-123-MIBG scintigraphy. Radiology 1985; 156: 789
   Google Scholar
• Shulkin B., Shapiro B., Francis I., Dorr R., Shen S.-W., Sisson J. C. Primary extra-adrenal pheochromocytoma: a case of positive I-123-MIBG scintigraphy with negative I-131-MIBG scintigraphy. Clin. Nucl. Med. 1986; 11: 851
   PubMed Web of Science ®Google Scholar
• Home T., Hawkins L. A., Britton K. E., Granowska M., Bouloux P., Besser G. M. Imaging of pheochromoctyoma and adrenal medulla with I-123-metaiodobenzylguanidine. Nucl. Med. Commun. 1984; 5: 763
   PubMedGoogle Scholar
• Bomanji J., Levison D. A., Flatman W. D., Home T., Besser G. M., Britton K. E. A quantitative approach to a pathophysiological study of apudoma using I-123-metaiodobenzylguanidine (MIBG). Nuklearmedizin 1986; 25: A57
   Google Scholar
• Shapiro B. (1988) MIBG in the management of neuroendocrine tumors. presented at International Congress on Advances in Management of Malignancies, Ascoli PicenoItaly, May, 3 to 61988. Conference Abstracts: Aprim, Pisa, Italy, 129
   Google Scholar
• Shapiro B., Copp J. E., Sisson J. E., Eyre P. L., Wallis J., Beierwaltes W. H. 1-131-metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases (441 Studies). J. Nucl. Med. 1985; 26: 576
   PubMed Web of Science ®Google Scholar
• Shapiro B. (1987) MIBG in the diagnosis and therapy of neuroblastoma and pheochromocytoma. Proceedings of the International Symposium on Recent Advance in Nuclear Medicine, UdineItaly, October, 2 to 31987, E. Cattaruzzi, E. Englaro, O. Geatti. Surin Biomedica, 11
   Google Scholar
• Valk T. W., Frager M. S., Gross M. D., Sisson J. C., Wieland D. M., Swanson D. P., Mangner T. J., Beierwaltes W. H. Spectrum of pheochromocytoma in multiple endocrine neoplasia: a scintigraphic portrayal using 1-131-metaiodobenzylguanidine. Ann. Int. Med. 1981; 94: 762
   PubMed Web of Science ®Google Scholar
• Sisson J. C., Shapiro B., Beierwaltes W. H. Scintigraphy with 1-131 MIBG as an aid to the treatment of pheochromocytomas in patients with the MEN-2 syndromes. Henry Ford Med. J. 1984; 32: 254
   PubMedGoogle Scholar
• Kalff V., Shapiro B., Lloyd R., Sisson J. C., Holland K., Nakajo M., Beierwaltes W. H. The spectrum of pheochromocytoma in hypertensive patients with neurofibromatosis. Arch. Intern. Med. 1982; 142: 2092
   PubMed Web of Science ®Google Scholar
• Glowniak J. V., Shapiro B., Sisson J. C., Thompson N. W., Coran A. G., Lloyd R. V., Kelsch R. C., Beierwaltes W. H. Familial extra-adrenal pheochromocytoma: a new syndrome. Arch. Int. Med. 1985; 145: 257
   PubMedGoogle Scholar
• Kalff V., Shapiro B., Lloyd R. V., Nakajo M., Sisson J. C., Beierwaltes W. H. Bilateral pheochromocytomas. J. Endocrinol. Invest. 1984; 7: 387
   PubMedGoogle Scholar
• Shapiro B., Sisson J. C., Lloyd R., Nakajo M., Satterlee W., Beierwaltes W. H. Malignant pheochromocytoma: clinical, biochemical and scintigraphic characterization. Clin. Endocrinol. 1084; 20: 189
   Google Scholar
• Bravo E. L., Gifford R. W. Pheochromocytoma: diagnosis, localization and management. N. Engl. J. Med. 1986; 311: 1298
   Google Scholar
• Levine S. N., McDonald J. C. The evaluation and management of pheochromocytomas. Advances in Surgery, J. T. Shire. Year Book Medical Publishers, New York, NY 1984; 17: 281
   Google Scholar
• VanHeerden J. A., Sheps S. G., Hamberger B., Sheedy P. F., Poston J. G., ReMine W. H. Pheochromocytoma: current status and changing trends. Surgery 1982; 91: 367
   PubMedGoogle Scholar
• Manger W. M., Gifford R. W. Hypertension secondary to pheochromocytoma. Bull. New York Acad. Med. 1982; 58: 139
   PubMedGoogle Scholar
• Thompson N. W., Alio M. D., Shapiro B., Sisson J. C., Beierwaltes W. H. Extra-adrenal and metastatic pheochromocytoma: the role of 131-I-metaiodobenzylguanidine (131-I-MIBG) in localization and management. World J. Surg. 1984; 8: 605
   PubMedGoogle Scholar
• Francis I. R., Glazer G. M., Shapiro B., Sisson J. C., Gross B. H. Complementary roles of CT scanning and I-131-MIBG scintigraphy in the diagnosis of pheochromocytoma. AJR 1983; 141: 719
   PubMed Web of Science ®Google Scholar
• Glazer G. M., Gross B. H., Orringer M. B., Buda J. A., Francis I. R., Shapiro B. Computed tomography of pericardial masses: further observations and comparisons with echocardiography. J. Comput. Assist. Tomogr. 1984; 8: 895
   PubMedGoogle Scholar
• Laursen K., Damgaard-Pedersen K. CT for pheochromocytoma diagnosis. AJR 1980; 134: 277
   PubMedGoogle Scholar
• Fink I. J., Reinig J. W., Dwyer A. J., Doppman J. L., Linehan W. M., Keiser H. R. MR imaging of pheochromocytomas. J. Comput. Assist. Tomogr. 1985; 9: 454
   PubMedGoogle Scholar
• Schultz C. L., Haaga J. R., Fletcher B. D., Alfidi R. J., Schultz M. A. Magnetic resonance imaging of the adrenal glands: A comparison with computed tomography. AJR 1984; 143: 1235
   PubMedGoogle Scholar
• Rossi P., Young I. S., Panke W. F. Techniques, usefulness, and hazards of arteriography of pheochromocytoma: review of 99 cases. JAMA 1968; 205: 547
   PubMedGoogle Scholar
• Jones D. H., Allison D. J., Hamilton C. A., Reid J. L. Selective venous sampling in the diagnosis and localization of pheochromocytoma. Clin. Endocrinol. 1979; 10: 179
   PubMed Web of Science ®Google Scholar
• Harrison T. S., Seaton R. F., Cerney J. C. Localization of pheochromocytoma by caval catheterization. Arch. Surg. 1967; 95: 339
   PubMedGoogle Scholar
• Bowerman R. A., Silver T. M., Jaffe M. J., Stuck K. J., Hinerman D. L. Sonography of adrenal pheochromocytomas. AJR 1981; 137: 1227
   PubMedGoogle Scholar
• Shapiro B., Sisson J. C. Sympatho-adrenal imaging with radioiodinated metaiodobenzylguanidine. Atlas of Nuclear Medicine, Nostrand D. Vo, S. Baum. J.B. Lippincott Co., Philadelphia 1988; 72
   Google Scholar
• Shapiro B., Sisson J. C., Eyre P., Copp J. E., Dmuchowski C., Beierwaltes W. H. 131-I-MIGB, a new agent in diagnosis and treatment of pheochromocytoma. Cardiology (Basel) 1985; 72: 137
   PubMedGoogle Scholar
• Anon. Clinical value of adrenomedullary scintigraphy with 131I-MIBG. Nucl. Compact 1983; 14: 318
   Google Scholar
• Baulieu J. L., Guilloteau D., Chambon C., Viel C., Baulieu F., Itti R., Pourcelot L., Besnard J. C. Meta-iodobenzylguanidine (mIBG) scintigraphy: a one year experience. J. Nucl. Med. 1984; 25(5)P111
   Google Scholar
• Ackery D. M., Tippett P. A., Condon B. R., Sutton H. E., Wyeth P. New approach to the localization of pheochromocytoma: imaging with iodine-131-meta-iodobenzylguanidine. Br. Med. J. 1984; 288: 1587
   PubMedGoogle Scholar
• Swansen S. J., Brown M. L., Sheps S. G., Sizemore G. W., Gharib H., Grant C. S., Van Heerden J. A. Use of 131-I-MIBG scintigraphy in the evaluation of suspected pheochromocytoma. Mayo Clin. Proc 1985; 60: 299
   PubMedGoogle Scholar
• Chatal J. F., Charbonnel B. Comparison of lodobenzylguanidine imaging with computed tomography in locating pheochromocytoma. J. Clin. Endocrinol. Metab. 1985; 61: 769
   PubMed Web of Science ®Google Scholar
• Jaffe N. Neuroblastoma: review of the literature and an examination of factors contributing to its enigmatic character. Cancer Treat. Rev. 1976; 3: 61
   PubMed Web of Science ®Google Scholar
• D'Angio G. J. Neuroblastoma overview-1986. Med. Ped. Oncol. 1987; 15: 159
   PubMedGoogle Scholar
• Treuner J., Feine U., Niethammer D., Muller-Schaumburg W., Meinke J., Eibach E., Dopfer R., Klingebiel T., Grumbach S. Scintigraphic imaging of neuroblastoma with 1-131-MIBG. Lancet 1984; 1: 333
   PubMedGoogle Scholar
• Geatti O., Shapiro B., Sisson J. C., Hutchinson R. J., Mallette S., Eyre P., Beierwaltes W. H. 131-I-metaiodobenzylguanidine (131-I-MIBG) scintigraphy for the location of neuroblastoma: preliminary experience in 10 cases. J. Nucl. Med. 1985; 26: 736
   PubMed Web of Science ®Google Scholar
• Kimmig B., Brandeis W. E., Eisenhut M. Scintigraphy of neuroblastoma with 131I-MIBG. J. Nucl. Med. 1984; 25: 773
   PubMed Web of Science ®Google Scholar
• Lumbroso J., Hartmann O., Lemerle J., Coornaert S., Desplanches G., Menard F., Gardet P., Schlumberger M., Parmentier C. Scintigraphic detection of neuroblastoma using 131-1 and 123-1 labelled metaiodo-benzylguanidine. Eur. J. Nucl. Med. 1985; 11: A16
   Google Scholar
• Hattner R. S., Huberty J. P., Engelstad B. L., Gooding C. A., Ablin A. R. Location of m(iodo 131I) benzylguanidine in neuroblastoma. AJR 1984; 143: 373
   PubMedGoogle Scholar
• Shulkin B. L., Shapiro B. Radio-iodinated Metaiodobenzylguanidine in the Management of Neuroblastoma. Neuroblastoma: Tumor Biology and Treatment, C. Pochedly, C. Tebbe. CRC Press, Boca Raton, FL 1988, in press.
   Google Scholar
• Heyman S., Evans A. E. 1-131 metaiodobenzylguanidine (I-131-MIBG) in the diagnosis of neuroblastoma. J. Nucl. Med. 1986; 27: 931
   Google Scholar
• Feine U., Treuner J., Niethammer D. Erste untenshungen zur scinti-graphischen darstellung von neuroblastomen mit 131-J-meta-benzlyl-guanidin. Nucl. Compact 1984; 15: 23
   Google Scholar
• Hoefnagel C. A., DeKraker J., Marcuse H. R., Voute P. A. Detection and treatment of neural crest tumors using I-131-meta-iodobenzlyguanidine. Europ. J. Nucl. Med. 1985; 11: A17
   PubMedGoogle Scholar
• Shulkin B., Shen S.-W., Sisson J. C., Shapiro B., Hutchinson R., Beierwaltes W. H. Normal and abnormal 131-I-meta-iodobenzylguanidine scintigraphy of the extremities. J. Nucl. Med. 1987; 28: 315
   PubMedGoogle Scholar
• Bomanji J., Levison D. A., Flatman W. D., Home T., Bouloux P. M. G., Ross G., Britton K. E., Besser G. M. Uptake of Iodine-123 MIBG by pheochromocytomas, paragangliomas and neuroblastomas: a histological comparison. J. Nucl. Med. 1987; 28: 973
   PubMed Web of Science ®Google Scholar
• Pearse A. G. E., Polak J. M. Endocrine tumors of neural crest origin: neurolophomas, apudomas and the APUD concept. Med. Biol. 1974; 52: 3
   PubMedGoogle Scholar
• Von Moll L., McEwan A. J., Shapiro B., Sisson J. C., Gross M. D., Lloyd R., Beals F., Beierwaltes W. H., Thompson N. W., Lloyd R. 131I-MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J. Nucl. Med. 1987; 28: 979
   PubMedGoogle Scholar
• Hoefnagel C. A., Voute P. A., DeKraker J., Marcuse H. R. Radionuclide diagnosis and therapy of neural crest tumors using Iodine-131 metaiodobenzylguanidine. J. Nucl. Med. 1987; 28: 308
   PubMed Web of Science ®Google Scholar
• Smit A. S., Van Essen L. H., Hollema H., Muskiet F. A. J., Piers D. A. Meta 1-131-iodobenzylguanidine uptake in a nonsecreting paraganglioma. J. Nucl. Med. 1984; 25: 984
   PubMedGoogle Scholar
• Fischer M., Kamanabroo D., Sonderkamp H., Proske T. Scintigraphic imaging of carcinoid tumors with 131I-metaiodobenzylguanidine. Lancet 1984; 2: 165
   PubMedGoogle Scholar
• Feldman J. M., Blinder R. A., Lucas K. J., Coleman R. E. Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors. J. Nucl. Med. 1986; 27: 1691
   PubMed Web of Science ®Google Scholar
• Sone T., Fukunaga M., Otsuka N., Morita R., Muranaka A., Yanagimoto S., Tomonitsu T., Nakayama H., Harada T. Metastatic medullary thyroid cancer: localization with iodine-131 metaiodobenzylguanidine. J. Nucl. Med. 1985; 26: 604
   PubMed Web of Science ®Google Scholar
• Endo K., Shiomi K., Kasagi K., Konishi J., Torizuka K., Nakao K., Tanimura H. Imaging of medullary thyroid cancer with 131-I-MIBG. Lancet 1984; 2: 233
   PubMedGoogle Scholar
• Hilditch T. E., Connell J. M., Elliot A. T., Murray T., Reed N. S. Poor results with technetium-99m (V) DMS and iodine-131 MIBG in the imaging of medullary thyroid carcinoma. J. Nucl. Med. 1986; 27: 1150
   PubMedGoogle Scholar
• Nakajo M., Taguchi M., Shimabukuo K., Shinohara S. Iodine-131-MIBG uptake in a small cell caricnoma of the lung. J. Nucl. Med. 1986; 27: 1785
   PubMedGoogle Scholar
• Kline R. C., Swanson D. P., Wieland D. M., Thrall J. H., Gross M. D., Pitt B., Beierwaltes W. H. Myocardial imaging in man with 1-123 meta-iodobenzylguanidine. J. Nucl. Med. 1981; 22: 129
   PubMed Web of Science ®Google Scholar
• Rabinovitch M. A., Rose C. P., Chartrand G., Rouleau J. L., Weiland D. M., Burgess J. H., Rosenthail L. Impaired myocardial retenion of 1-131 metaiodobenzylguanidine (MIBG) in chronic volume-overload heart failure. J. Nucl. Med. 1986; 27: 1068
   Google Scholar
• Wellman H., Zipes D., Tulim M., Minardo J., Wieland D., Liang Y. 123-I-MIBG demonstrating the feasibility of imaging myocardial conduction pathway interruption in a dog model. Nuklearmedizin 1986; 25: A30
   Google Scholar
• Glowniak J. V., Turner F. E., Gray L. L., Palac R. T., Lagunas-Solar M. C., Hosenpud J. D. I-123 meta-iodobenzylguanidine (MIBG) cardiac imaging in idiopathic congestive cardiomyopathy. J. Nucl. Med. 1987; 28: 667
   Google Scholar
• Sisson J. C., Wieland D. M., Sherman P., Mangner T. J., Tobes M. C., Jaques S. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J. Nucl. Med. 1987; 28: 1620
   PubMed Web of Science ®Google Scholar
• Sisson J. C., Shapiro B., Meyers L., Mallette S., Mangner T. J., Wieland D. M., Glowniak J. V., Sherman P., Beierwaltes W. H. Metaiodo-benzylguanidine to map scintigraphically the adrenergic nervous system in man. J. Nucl. Med. 1987; 28: 1625
   PubMed Web of Science ®Google Scholar
• Shapiro B. Therapy of pheochromocytoma. Mich. Postgrad. Rev. 1985; 2: 103
   Google Scholar
• Drasin H. Treatment of a malignant pheochromocytoma. West. J. Med. 1978; 128: 106
   PubMedGoogle Scholar
• Keiser H. R., Goldstein D. S., Wade J. L., Douglas F. L., Averbuch S. D. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 1985; 7(1)1
   Google Scholar
• Sisson J. C., Shapiro B., Beierwaltes W. H., Nakajo M., Glowniak J., Mangner T. J., Carey J. E., Swanson D. P., Copp J., Satterlee W., Wieland D. M. Treatment of malignant pheochromocytoma with a new radiopharmaceutical. Trans. Assoc. Amer. Phys. 1983; 96: 209
   PubMedGoogle Scholar
• Sisson J. C., Shapiro B., Beierwaltes W. H., Glowniak J. V., Nakajo M., Mangner T. J., Carey J. E., Swanson D. P., Copp J. E., Satterlee W. G., Wieland D. M. Radiopharmaceutical treatment of malignant pheochromocytoma. J. Nucl. Med. 1984; 25: 197
   PubMedGoogle Scholar
• McDougall I. R. Teaching editorial: malignant pheochromocytoma treated by I-131-MIBG. J. Nucl. Med. 1984; 25: 249
   PubMedGoogle Scholar
• Shulkin B. L., Sisson J. C., Koral K. F., Shapiro B., Wang X., Johnson J. Conjugate-view gamma camera method for estimating tumor uptake of Iodine-131-metaiodobenzylguanidine. J. Nucl. Med. 1988; 29: 542
   PubMedGoogle Scholar
• Shulkin B. L., Shen S.-W., Meyers L., Shapiro B., Koral K., Sisson J. C. Dosimetry of I-131-MIBG in pheochromocytoma. Proceedings of the Fourth World Congress of Nuclear Medicine and Biology. Buenos Aires, 1986; 201, Abstract 743
   Google Scholar
• Sisson J. C., Hutchinson R., Johnson J., Mallette S., Carey J. E., Shapiro B., Beierwaltes W. H. Acute toxicity of therapeutic 131I-MIBG relates more to whole body than to blood radiation dosimetry. J. Nucl. Med. 1987; 23: 618
   Google Scholar
• Fischer M., Winterberg B., Muller-Rensing R., Friedmann J., Zidek W., Vetter H. Nuklearmedizinishe therapie des pheochromocytoms. Nuc. Compact. 1983; 14: 172
   Google Scholar
• Vetter H., Fischer M., Muller Rensing R., Vetter W., Winterberg B. 131I-MIBG in the treatment of malignant pheochromocytomas. Lancet 1983; 2: 107
   PubMed Web of Science ®Google Scholar
• Shapiro B., Fischer M. Summary of the proceedings of a workshop on 131-I-metaiodobenzylguanidine held at Schloss Wilkinghege, Munster, West Germany, September 27, 1974. Nucl. Med. Commun. 1985; 6: 179
   Google Scholar
• Shapiro B., Geatti O., Sisson J. C., Hutchinson R., Mallette S., Eyre P., Shen S.-W., Shulkin B., Mangner T. J., Beierwaltes W. H. Diagnosis and therapy of neuroblastoma (neuro) 131I-metaiodobenzyl-guanidine (131I-MIBG). Nucl. Med. Commun. 1985; 6: 555
   Google Scholar
• Shen S.-W., Sisson J. C., Hutchinson R., Shapiro B., Shulkin B., Geatti O., Mallette S., Eyre P., Mangner T., Beierwaltes W. H. The progressive and diffuse nature of neuroblastoma: treatment with 1-131 metaiodo-benzylguanidine (I-131-MIBG). J. Nucl. Med. 1985; 26: P75
   Google Scholar
• Proceedings of Conference on “The Role of MIBG in Therapy Diagnosis and Monitoring of Neuroblastoma”, nineteen contributions, A. M. Mauer, R. Mastrangelo. Med. Ped. Oncol., 1987; 15: 157
   Google Scholar
• Sinzinger H., Renner F., Granegger S. 131-I-MIBG imaging of carcinoids and apudomas. Europ. J. Nucl. Med. 1985; 11: A17
   PubMedGoogle Scholar
• Shapiro B., Gross M. D. Radiochemistry, biochemistry, and kinetics of 131-I-metaiodobenzylguanidine (MIBG) and 123-I-MIBG: clinical implications of the use of 123-I-MIBG. Med. Ped. Oncol. 1987; 15: 170
   PubMedGoogle Scholar
• Jonsson B. A., Strand S. E. Auger electron emitters as therapeutic agents or sources of hazard in diagnosis-a review, in Radionuclides for Therapy. Proceedings of the 4th Bottstein Colloquium, WurenlingerSwitzerland. P. A. Schubiger, P. H. Hasler. Editiones Roche, BasleSwitzerland 1986; 91
   Google Scholar
• Sisson J. C. Radionuclide Therapy for Malignancy: Influences of Physical Characteristics of Radionuclides and Experience with Radiolabelled meta-Iodobenzylguanidine. Nuclear Medicine in Oncology, Clinics in Oncology, D. Ackery, V. Batty. W. B. Saunders Company, London 1986; 5: 1
   Google Scholar
• Hoefnagel C. A., Den Hartog Jager F. C., Van Gennip A. M., Marcuse H. R., Taal B. G. Diagnosis and treatment of a carcinoid tumor using iodine 131 metaiodobenzylguanidine. Clin. Nucl. Med. 1986; 3: 150
   Google Scholar